Dan on for Francois Brisebois's questions to Apellis Pharmaceuticals Inc (APLS) leadership • Q3 2024
Question
Representing Francois Brisebois of Oppenheimer, Dan asked for color on the specific factors that contributed to the recent uptick in new patient starts for SYFOVRE.
Answer
COO Adam Townsend attributed the stable rebound in new patient share to approximately 50% to the successful execution of their commercial plan. He emphasized that key messages around SYFOVRE's strong efficacy, increasing effects over time, flexible dosing, and extensive real-world experience are resonating with both existing and new prescribers.